BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition

Although targeting oncogenic mutations in the BRAF serine/threonine kinase with small molecule inhibitors can lead to significant clinical responses in melanoma, it fails to eradicate tumors in nearly all patients. Successful therapy will be aided by identification of intrinsic mechanisms that prote...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Haq, Rizwan, Yokoyama, Satoru, Hawryluk, Elena B., Jönsson, Göran B., Frederick, Dennie Tompers, McHenry, Kevin, Porter, Dale, Tran, Thanh-Nga, Love, Kevin T., Langer, Robert, Anderson, Daniel G., Garraway, Levi A., Duncan, Lyn McDivitt, Morton, Donald L., Hoon, Dave S. B., Wargo, Jennifer A., Song, Jun S., Fisher, David E.
Formato: Artigo
Lenguaje:Inglês
Publicado: National Academy of Sciences 2013
Materias:
Biological Sciences
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3600451/
https://ncbi.nlm.nih.gov/pubmed/23447565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1205575110
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares